Association of the Leu72Met polymorphism of the ghrelin gene with the risk of Type 2 diabetes in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study

What Was Tested

Researchers studied Ghrelin in this randomized controlled trial publication.

Ghrelin is a gut-brain regulatory peptide stimulating appetite and controlling energy balance.

Who Took Part

The abstract describes 2 subjects taking part.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

A total of 522 subjects with IGT were randomized into either an intervention or a control group and DNA was available from 507 subjects.

The Leu72Met polymorphism was screened by the restriction fragment length polymorphism method.

How the Study Was Run

The researchers set it up as a randomized and multicenter study.

Because people in this Ghrelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

More than one site took part, so the subjects came from several places.

DPS was a longitudinal intervention study carried out in five participating centres in Finland.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Finland, Ghrelin, Glucose Intolerance, Health Surveys, Peptide Hormones and Polymorphism, Genetic.

What This Means in Plain Language

The paper is a randomized and multicenter study of Ghrelin in 2 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2006 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the Ghrelin compound page, all human trials.